Home/Filings/4/0001225208-24-004959
4//SEC Filing

MUSSALLEM MICHAEL A 4

Accession 0001225208-24-004959

CIK 0001099800other

Filed

Apr 3, 8:00 PM ET

Accepted

Apr 4, 6:26 PM ET

Size

15.2 KB

Accession

0001225208-24-004959

Insider Transaction Report

Form 4
Period: 2024-04-04
MUSSALLEM MICHAEL A
DirectorChairman & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2024-04-04$36.75/sh+29,350$1,078,61333,835.82 total
  • Sale

    Common Stock

    2024-04-04$93.72/sh2,712$254,16930,923.82 total
  • Sale

    Common Stock

    2024-04-04$92.70/sh16,618$1,540,4894,485.82 total
  • Exercise/Conversion

    Employee Stock Option (Right to Acquire)

    2024-04-0429,35029,350 total
    Exercise: $36.75From: 2017-06-11Exp: 2024-05-10Common Stock (29,350 underlying)
  • Sale

    Common Stock

    2024-04-04$94.19/sh200$18,83833,635.82 total
  • Sale

    Common Stock

    2024-04-04$91.54/sh9,820$898,92321,103.82 total
Holdings
  • Common Stock

    (indirect: By Trust)
    4,038,377
Footnotes (5)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
  • [F2]This transaction was executed in multiple trades at prices ranging from $94.185 to $94.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]This transaction was executed in multiple trades at prices ranging from $93.130 to $94.130. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]This transaction was executed in multiple trades at prices ranging from $91.120 to $92.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]This transaction was executed in multiple trades at prices ranging from $92.125 to $93.120. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file

Issuer

Edwards Lifesciences Corp

CIK 0001099800

Entity typeother

Related Parties

1
  • filerCIK 0001204551

Filing Metadata

Form type
4
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 6:26 PM ET
Size
15.2 KB